Premium
Impact of sorafenib on health‐related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation
Author(s) -
Miyake Hideaki,
Kurahashi Toshifumi,
Yamanaka Kazuki,
Kondo Yutaka,
Takenaka Atsushi,
Inoue Takaaki,
Fujisawa Masato
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09437.x
Subject(s) - medicine , sorafenib , renal cell carcinoma , quality of life (healthcare) , observational study , refractory (planetary science) , nephrectomy , prospective cohort study , population , kidney , hepatocellular carcinoma , physics , nursing , environmental health , astrobiology
Study Type – Therapy (case series)
Level of Evidence 4 OBJECTIVE To characterize the impact of sorafenib treatment on health‐related quality of life (HRQL) in Japanese patients with mRCC. PATIENTS AND METHODS We performed a prospective observational study including 85 consecutive patients undergoing radical nephrectomy who were diagnosed as having mRCC refractory to cytokine therapy and subsequently treated with sorafenib for at least 3 months. HRQL in these patients was assessed using the Medical Outcomes Study 36‐Item Short Form (SF‐36). RESULTS Before treatment all eight scores in the 85 patients were significantly inferior to those in the age‐matched control population in Japan. Three months after sorafenib treatment, one score (mental health) in the 85 patients was significantly higher than what it was before treatment. Three scores (body pain, role limitations because of emotional problems, mental health) in patients who had some degree of tumour shrinkage were significantly better than those in the remaining patients, while there were no significant differences in all but one score (social function) between patients with and without severe AEs. Furthermore, there were no significant differences in any scores 3, 6 and 12 months after sorafenib treatment in 26 patients who could be followed for at least 12 months. CONCLUSIONS Despite non‐randomized study including a comparatively small number of patients, the findings of the present study suggest that sorafenib treatment may not impair HRQL in patients with mRCC, and HRQL in patients receiving sorafenib is likely to be affected by the efficacy rather than AEs during treatment.